What is the efficacy of chemotherapy in the treatment of renal cell carcinoma (RCC)?

Updated: Jun 08, 2020
  • Author: Kush Sachdeva, MD; Chief Editor: E Jason Abel, MD  more...
  • Print

A phase 2 trial of weekly intravenous (IV) gemcitabine (600 mg/m2 on days 1, 8, and 15) with continuous infusion fluorouracil (150 mg/m2/d for 21 d in 28-d cycle) in patients with metastatic renal cell cancer (RCC) produced a partial response rate of 17%. [66] No complete responses were noted. Eighty percent of patients had multiple metastases, and 83% had received previous treatment. The mean progression-free survival duration of 28.7 weeks was significantly longer than that of historic controls. [66]

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!